Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
44.12 EUR | +0.17% | +3.02% | -20.23% |
Apr. 25 | Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 18 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
Sales 2024 * | 59.72M 64.94M | Sales 2025 * | 77.53M 84.31M | Capitalization | 782M 851M |
---|---|---|---|---|---|
Net income 2024 * | -14M -15.22M | Net income 2025 * | 1M 1.09M | EV / Sales 2024 * | 12.8 x |
Net cash position 2024 * | 15.17M 16.49M | Net cash position 2025 * | 27.2M 29.58M | EV / Sales 2025 * | 9.74 x |
P/E ratio 2024 * |
-51.7
x | P/E ratio 2025 * |
-1,477
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
0.55% | Free-Float | 42.17% |
1 week | +3.02% | ||
Current month | +8.57% | ||
1 month | +10.74% | ||
3 months | -19.22% | ||
6 months | -28.24% | ||
Current year | -20.23% |
Managers | Title | Age | Since |
---|---|---|---|
Stefan Glombitza
CEO | Chief Executive Officer | - | 16-09-30 |
Enno Spillner
DFI | Director of Finance/CFO | 55 | 23-03-31 |
Andreas Seidl
CTO | Chief Tech/Sci/R&D Officer | - | 22-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Olaf Stiller
FOU | Founder | 47 | 06-12-31 |
Peter Wendeln
BRD | Director/Board Member | 59 | - |
Klaus Röhrig
BRD | Director/Board Member | 47 | 20-12-09 |
Date | Price | Change |
---|---|---|
24-05-20 | 44 | -0.11% |
24-05-17 | 44.35 | +0.68% |
24-05-16 | 44.05 | -2.22% |
24-05-15 | 45.05 | +4.04% |
24-05-14 | 43.3 | +2.49% |
Delayed Quote Börse Stuttgart, May 20, 2024 at 05:00 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- FYB Stock
- FYB Stock